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Introduction
Granzymes are cytotoxic serine proteases used by cytotoxic 
lymphocytes (CLs) to destroy virus-infected and malignant 
cells. They are delivered into the cytoplasm of the target cell by 
the pore-forming protein perforin. Once inside the target cell, 
granzymes cleave specifi  c proteins and trigger apoptosis (for 
review see Russell and Ley, 2002).
Humans have 5 granzymes (A, B, H, K, and M), 
whereas mice have 10 granzymes, having duplicated the an-
cestral granzyme B/H gene. In the absence of reported hu-
man granzyme defi  ciency, understanding of granzymes has 
been built by experimental approaches involving knock-
out mice or the use of purifi  ed granzymes on cells or cell 
  extracts. For example, loss of granzyme A (GrA) or granzyme 
B (GrB) in mice is not catastrophic, but loss of both results 
in a severe immunological   defect. Numerous studies using 
purifi  ed human and rodent granzymes have identifi  ed sub-
strates, regulators, and traffi  cking pathways, whereas granzyme-
defi   cient mice are widely used to probe the contribution 
and importance of granzymes to immunity (Russell and 
Ley, 2002).
GrA and GrB are the major and most-studied granzymes. 
GrA cleaves substrates after basic residues and induces caspase-
independent apoptosis (for review see Lieberman and Fan, 2003). 
GrB cleaves after acidic residues, primarily Asp, and induces 
apoptosis by directly or indirectly activating caspases, and by 
cleaving other proapoptotic proteins such as Bid or ICAD/DFF45 
(for review see Trapani and Sutton, 2003). Studies using CL from 
knockout mice confi  rm that GrA and GrB trigger distinct apop-
totic pathways and are thus complementary (Pardo et al., 2004).
The high sequence homology and conserved primary 
cleavage specifi  city of human and mouse granzymes has led to 
widespread and interchangeable use of human and mouse en-
zymes in experimental systems, usually without side-by-side 
comparisons being made. Because GrA is a unique gene in both 
species, it is reasonable to assume an orthologous relationship 
between mouse GrA (mGrA) and human GrA (hGrA), but re-
cent structural data show that they have distinct extended sub-
strate specifi  cities (Bell et al., 2003), raising the possibility that 
they possess distinct functions. The situation with GrB is even 
more complicated. hGrB has multiple paralogues in the mouse 
and rat, suggesting that the roles fulfi  lled by a single enzyme in 
humans may be split among several in rodents (Pham et al., 
1996; Revell et al., 2005).
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A
pproximately 2% of mammalian genes encode 
proteases. Comparative genomics reveals that 
those involved in immunity and reproduction show 
the most interspecies diversity and evidence of positive se-
lection during evolution. This is particularly true of gran-
zymes, the cytotoxic proteases of natural killer cells and 
CD8
+ T cells. There are 5 granzyme genes in humans and 
10 in mice, and it is suggested that granzymes evolve to 
meet species-speciﬁ  c immune challenge through gene dupli-
cation and more subtle alterations to substrate speciﬁ  city. 
We show that mouse and human granzyme B have dis-
tinct structural and functional characteristics. Speciﬁ  cally, 
mouse granzyme B is 30 times less cytotoxic than human 
granzyme B and does not require Bid for killing but re-
gains cytotoxicity on engineering of its active site cleft. We 
also show that mouse granzyme A is considerably more 
cytotoxic than human granzyme A. These results demon-
strate that even “orthologous” granzymes have species-
speciﬁ  c functions, having evolved in distinct environments 
that pose different challenges.
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Without detailed comparative knowledge of the character-
istics of human and mouse granzymes, data from mice cannot 
be extrapolated with confi  dence to humans. Here, we show that 
the cytotoxicity, substrate preferences, and inhibitor  interactions 
of hGrB and mGrB are substantially different. We also extend 
the study of Bell et al. (2003) to show that hGrA and mGrA 
have markedly different cytotoxic potential. Such differences 
probably refl  ect the two species’ response to differing immune 
evolutionary pressure.
Results
hGrB is more cytotoxic than mGrB
Granzyme cytotoxicity can be studied in vitro by adding puri-
fi  ed perforin and granzyme to cultured cells and monitoring cell 
survival (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200606073/DC1). Keeping the concentration of  perforin 
constant, granzyme cytotoxicity is quantitated using a dose–
  response approach, in which the amount of granzyme required 
to kill 50% of the target cells (EC50) is measured (Sun et al., 
2004). Initial experiments using this system with either human 
or mouse cells showed that hGrB is substantially more cyto-
toxic than mGrB.
This apparent difference in cytotoxicity between mGrB 
and hGrB was confi  rmed using several different targets, as cell 
type–dependent differences in susceptibility to granzymes have 
been reported (Pardo et al., 2002). In one human cell line and 
three mouse cell lines examined in detail, hGrB was consis-
tently more cytotoxic than mGrB (Fig. 1). With the exception of 
Figure 1.  hGrB is more cytotoxic than mGrB in perforin-mediated cell 
death. (A) Cytotoxicity proﬁ  les of mGrB and hGrB on mouse and human 
cells. Cells were incubated for 1 h with hGrB (solid line) or mGrB (dashed 
line) in the presence of perforin. Cell survival was assessed after 24 h by 
MTT assay. A representative experiment is shown for each cell line, and the 
amount of enzyme required to kill 50% of the cells (EC50) is indicated on the 
graph. (B) Summary of data from replicate experiments. (C) Comparison of 
GrB cytotoxicity in the presence of SLO. P815 cells were exposed to mGrB 
or hGrB as described in A, except SLO was used instead of perforin.
Figure 2.  mGrB and hGrB have distinct substrate proﬁ  les and cytotoxic 
mechanisms. (A) mGrB inefﬁ  ciently cleaves an optimal hGrB peptide sub-
strate. Michaelis plots of peptide substrate hydrolysis by human (h) and 
mouse (m) GrB. Calculated speciﬁ  city constants for each enzyme–substrate 
pair are tabulated below the plots. (B) mGrB inefﬁ  ciently cleaves Bid. 
35S-labeled mouse procaspase 3 or mouse Bid were incubated with hGrB 
or mGrB at 37°C for 30 min. 100 μM z-VAD was included in parallel reac-
tions to prevent the second step in caspase 3 activation. Products were 
separated by 15% SDS-PAGE and visualized by ﬂ  uorography. (C) mGrB 
does not require Bid to kill cells. Bid+/+ (solid line) or Bid−/− (dashed 
line) mouse B cell lymphomas (Waterhouse et al., 2005) were incubated 
for 1 h with hGrB or mGrB in the presence of perforin. Cell survival was 
assessed after 24 h by MTT assay. EC50 values from replicate experiments 
are indicated below.FUNCTIONAL DIVERGENCE OF HUMAN AND MOUSE GRANZYMES • KAISERMAN ET AL. 621
YAC-1, cells were 10–60-fold more sensitive to hGrB (Fig. 1). 
Killing of mouse YAC-1 cells required similarly high levels of 
hGrB or mGrB, suggesting that a key substrate is low or absent 
in these cells. mGrB was also 30-fold less effective in killing 
mouse lymphoma cells (Fig. 2 C).
To test whether poorer uptake of mGrB explains its ineffi  -
cient killing, we compared accumulation of fl  uoresceinated 
mGrB and hGrB in Jurkat cells (Bird et al., 2005). No impair-
ment in the rate or extent of accumulation of mGrB versus hGrB 
was noted in these cells (Fig. S2, available at http://www.jcb.
org/cgi/content/full/jcb.200606073/DC1) or in the mouse P815 
and lymphoma cell lines used in this study. The differences in 
cytotoxicity between mGrB and hGrB also remained when the 
bacterial porin, streptolysin O (SLO) was used instead of perforin 
(Fig. 1 C). SLO admits proteins directly to the cytoplasm via 
transient plasma membrane pores (Walev et al., 2001) and pro-
vides a perforin-independent mechanism for granzyme uptake, 
as shown by its ability to deliver mutant granzymes that cannot 
be delivered by perforin (Bird et al., 2005). The fact that mGrB 
killing is as ineffi  cient in SLO as it is in perforin suggests that 
there is no restriction in perforin-mediated delivery of mGrB. 
Thus, differences in uptake or delivery of hGrB and mGrB do 
not explain their markedly different cytotoxic potential.
mGrB-mediated cytotoxicity 
does not require Bid
To investigate the basis for the differences in cytotoxicity be-
tween mGrB and hGrB, we compared their activities on peptide 
substrates and on the natural substrates procaspase 3 and Bid 
(Metkar et al., 2003; Waterhouse et al., 2005). Combinatorial pep-
tide substrate analysis has identifi  ed the peptide IleGluXxxAsp¯ 
as an optimal recognition and cleavage sequence for hGrB 
and rat GrB (Thornberry et al., 1997; Harris et al., 1998). This 
appears in human and mouse Bid, and both are cleaved at this 
site by hGrB (Pinkoski et al., 2001). Although mGrB cleaves Bid 
(Thomas et al., 2001), the cleavage site has not been determined. 
A similar P4-P1 cleavage sequence is present on procaspase 3, 
but the downstream (P′) sequence differs from Bid. The 
  nomenclature of cleavage site positions of a protease substrate 
follows Schechter and Berger (1967). The protease cleaves 
the peptide bond between P1 and P1′. Adjacent residues in the 
N-terminal direction are numbered P2, P3, P4, etc. On the 
carboxyl side of the cleavage site, residues are numbered P2′, 
P3′, P4′, etc. The P1 residue is accommodated in the S1 pocket 
of the catalytic cleft, the P2 residue is accommodated in the S2 
pocket, and so forth.
mGrB and hGrB both cleaved the small peptide substrate 
Boc-AlaAlaAsp-thio benzyl ester (AAD-sbzl) with similar effi  -
ciency (Fig. 2 A, right), consistent with their known Aspase ac-
tivities, indicating that their apparent functional distinctions are 
not due to differences in ability to hydrolyse a P1(Asp)-P1′ 
bond. As expected, hGrB also effi  ciently cleaved IleGluThrAsp-
pNA (IETD-pNA; Fig. 2 A, left). In contrast, mGrB hydrolyzed 
IETD-pNA 30-fold less effi  ciently than hGrB (Fig. 2 A, left), 
suggesting that it cannot comfortably accommodate this peptide 
in its substrate binding pocket.
The markedly inferior ability of mGrB to cleave IETD-
pNA also suggested that it would not cleave full-length Bid or 
procaspase 3 effi  ciently. To test this, we produced 
35S-labeled 
mouse Bid and mouse procaspase 3 and incubated the protein 
with hGrB or mGrB. Under these conditions, complete  cleavage 
of Bid was achieved in 25 nM hGrB, whereas 2 μM mGrB 
failed to completely cleave Bid (Fig. 2 B, right). Thus, mGrB 
cleaves Bid 80–100-fold less effi  ciently than hGrB. In contrast, 
the two granzymes cleaved procaspase 3 with similar effi  ciency 
(Fig. 2 B, left), suggesting that other factors such as P′ residues 
also infl  uence cleavage (Table I and Fig. 3).
Previous studies using hGrB have indicated that Bid cleav-
age is a key event in GrB-mediated apoptosis (Goping et al., 
2003; Sutton et al., 2003; Waterhouse et al., 2005). GrB initiates 
procaspase 3 activation by cleaving it once, but full activation 
requires a second cleavage, autocatalytically or via another 
  caspase. This is illustrated in Fig. 2 B and Fig. S3 (available 
at http://www.jcb.org/cgi/content/full/jcb.200606073/DC1) by 
the inclusion of the caspase inhibitor z-VAD in the reactions. 
In vivo, this second cleavage step is prevented by inhibitor 
of apoptosis protein (IAP) bound to caspase 3 and will not 
occur unless IAP is displaced by Smac/Diablo released from 
mitochondria by Bid (Goping et al., 2003; Sutton et al., 
2003). Thus, in the absence of Bid, hGrB cannot drive full 
caspase 3 activation.
To examine the importance of Bid in mGrB-mediated apop-
tosis, we compared the ability of hGrB and mGrB to kill mouse 
cells lacking Bid. As reported previously (Waterhouse et al., 2005), 
Table I. Cleavage of Bid and phage display consensus peptides
Substrate
a mGrB hGrB
kcat KM kcat/KM kcat KM kcat/KM
s
−1 μMM
−1s
−1 s
−1 μMM
−1s
−1
Abz-IEPD¯SESQK(dnp)S 
 (wt Bid cleavage site)
0.049 ± 0.004 30.88 ± 2.48 1,575 ± 172 1.32 ± 0.09 18.96 ± 2.45 69,397 ± 10,161
Abz-IEPD¯SGSQK(dnp)S 
 (Bid site with P2′Gly)
0.65 ± 0.18 59.67 ± 2.92 10,915 ± 3,101 5.11 ± 0.27 22.06 ± 2.67 231,449 ± 30,585
Abz-LEYD¯LGALK(dnp)S 
 (Phage display sequence)
2.51 ± 0.16 23.48 ± 3.68 106,948 ± 18,094 0.008 ± 0.0004 122.9 ± 6.8 61.3 ± 4.5
Values presented are the mean ± SD (n = 3).
aPeptide substrates include aminobenzoyl (Abz), dinitrophenyl (dnp), and C-terminal serine to enhance peptide solubility. Arrow indicates P1-P1′ bond and 
cleavage site.JCB • VOLUME 175 • NUMBER 4 • 2006  622
hGrB effi  ciently killed mouse lymphoma cells containing Bid 
(EC50 2.5 U/ml), but was >1,000-fold less cytotoxic toward lym-
phoma cells lacking Bid (Fig. 2 C, left). In contrast, mGrB killed 
the Bid+/+ and Bid−/− cells with similar effi  ciency, indicating 
that Bid cleavage is not essential for mGrB cytotoxicity (Fig. 2 C, 
right). These observations cannot be explained by differences in 
procaspase 3 levels between these lines or by differences in the 
ability of mGrB or hGrB to cleave procaspase 3 either in vitro or 
in cell extracts (compare Fig. 2 B and Fig. S3). It is also unlikely 
that mGrB can circumvent Bid by directly and fully activating pro-
caspase 3, as z-VAD blocks the second cleavage event when pro-
caspase 3 is exposed to mGrB (Fig. 2 B and Fig. S3). Collectively, 
the aforementioned results indicate that mGrB and hGrB have 
similar but distinct substrate specifi  cities and that they trigger 
death differently.
Substrate phage display conﬁ  rms that 
hGrB and mGrB have distinct speciﬁ  cities
To compare the substrate specifi  cities of hGrB and mGrB, we 
used substrate phage display. Phage carry a variable  (randomized) 
nonameric peptide linked to a His tag, fused to a coat pro-
tein Phage adsorbed to nickel-agarose are treated with protease, 
and cleaved phage are analyzed after several rounds of capture 
and release.
The granzymes were used to probe a library in which the 
fourth residue of the nonamer had been fi  xed as Asp. As shown 
in Fig. 3, phage enriched by hGrB treatment displayed a P4-P3-
P2-P1-P1′-P2′-P3′ consensus sequence, [I/V][G/E]ADVLV. 
This closely matches the P4-P1 sequence previously identifi  ed 
by combinatorial peptide analysis  (Thornberry et al., 1997; 
Harris et al., 1998) and validates the phage display approach. In 
contrast, treatment with mGrB yielded the consensus sequence 
[I/L]X[F/Y]DXGV. Specifi  cally, the preferences at the P4, P2, 
and P2′ positions are different between mGrB and hGrB. mGrB 
shows an equal preference for Ile or Leu at P4 and an aromatic 
residue at P2, whereas hGrB strongly prefers Ile at P4 and has a 
relaxed requirement at P2. mGrB also has a very strong prefer-
ence for Gly at P2′, whereas hGrB has no obvious preference at 
this position.
To confi  rm that mGrB can cleave a substrate with the 
aforementioned characteristics, we synthesized a quenched-
 fl uorescence substrate peptide based on one of the phage se-
quences that met the consensus [L/I]X[F/Y]DXGX. This 
peptide abz-LEYDLGALK(dnp)S was cleaved by both mGrB 
and hGrB, but kinetic analysis showed that it is a 370-fold better 
substrate for mGrB (Table I, compare specifi  city constants). 
These results show that the consensus substrate sequences for 
hGrB and mGrB differ at the key P4, P2, and P2′ positions and 
indicate structural differences in the corresponding pockets in 
the catalytic clefts of the two enzymes.
Efﬁ  cient cleavage of Bid by mGrB requires 
a P2′ Gly
As shown in Fig. 2, mGrB cleaves Bid poorly but procaspase 3 
relatively well. The substrate phage display results suggest that 
mGrB requires Gly at the P2′ to effi  ciently cleave substrates, 
but both mouse and human Bid have Glu at this position. 
To determine whether P2′ Gly enhances cleavage by mGrB, we 
synthesized a peptide substrate based on the GrB cleavage site 
in mouse Bid (IEPD¯SESQ) and a derivative with P2′ Gly 
(IEPD¯SGSQ). Both hGrB and mGrB cleaved the wild-type 
(wt) Bid substrate, but hGrB cleaved it >40-fold more effi  -
ciently (Table I). This is consistent with the 30-fold difference 
in the ability of the two proteases to cleave IETD-pNA (Fig. 2 A). 
In contrast, mGrB cleaved the P2′ Gly substrate sevenfold bet-
ter than the wt Bid substrate, whereas hGrB showed a threefold 
improvement over cleavage of the wt sequence, consistent with 
the slight overrepresentation of Gly at P2′ in the phage display 
data (Fig. 3). Thus, mGrB prefers P2′ Gly in natural substrates, 
and its poor cleavage of Bid can be explained partly by lack of 
Gly at this position. Given the conservation of the P4-P1 se-
quence in Bid and procaspase 3 (IEXD), these results also ex-
plain why procaspase 3 is apparently a better substrate of mGrB 
than Bid (Fig. 2 B): mouse procaspase 3 has a P2′ Gly at its GrB 
cleavage site.
mGrB can be “humanized” by alteration 
of its S4/S3 subsite
The inability of mGrB to cleave after IETD suggested differ-
ences between mGrB and hGrB in the substrate binding cleft, 
presumably in the pockets that interact with the side chains of 
Figure 3.  Comparison of hGrB and mGrB cleavage speciﬁ  cities by sub-
strate phage display. (A) Statistical distribution of amino acids in sequences 
enriched in a P1 (Asp) substrate phage library cleaved by hGrB or mGrB 
(n = 70 and 102 peptides, respectively). ∆σ is a measure of the difference 
between observed and expected frequencies in terms of standard devia-
tion for each amino acid at each subsite (Matthews et al., 1994). A value 
of ∆σ ≥ 5 (black bars) is considered to represent a signiﬁ  cant deviation 
from the expected frequency. (B) Consensus cleavage sequences for mGrB 
and hGrB derived from phage display.FUNCTIONAL DIVERGENCE OF HUMAN AND MOUSE GRANZYMES • KAISERMAN ET AL. 623
the P4, P3, or P2 residues of a substrate. Inspection of the struc-
ture of hGrB bound to the tetrapeptide aldehyde inhibitor IEPD-
CHO (Rotonda et al., 2001) revealed that Asn218 in the S3 
pocket forms hydrogen bonds with the P3 Glu of the substrate, 
whereas Tyr174 in the S4 pocket undergoes hydrophobic inter-
actions with P4 Ile of the substrate (Fig. 4 A). These two resi-
dues are conserved in rat GrB and have been shown to infl  uence 
substrate specifi  city (Ruggles et al., 2004). In contrast, they are 
not conserved in mGrB (Fig. 4 B, Arg174 and Lys218). Thus, 
we predicted that mutating mGrB toward hGrB by replacing 
Arg174 with Tyr and Lys218 with Asn would enable it to more 
effi  ciently cleave IETD and Bid.
As shown in Fig. 5 A, mutated mGrB retained the ability 
to cleave AAD-sbzl and showed substantially enhanced activity 
on IETD-pNA, with kcat/Km values on both substrates similar to 
those of hGrB (compare Fig. 5 A with Fig. 2 A). In addition, the 
mutant mGrB showed enhanced ability to cleave Bid, together 
with a slight increase in the ability to cleave procaspase 3 (Fig. 5 B). 
This translated into an increased ability to kill the Bid+/+ 
  lymphomas (Fig. 5 C). Interestingly, the mutated mGrB also 
showed an increased ability to kill the Bid−/− lymphomas 
(Fig. 5 C), suggesting that rather than being simply converted to 
hGrB selectivity, it has gained the ability to cleave hGrB-  specifi  c 
targets (e.g., Bid) while retaining the ability to cleave mGrB-
specifi  c targets. Finally, mutant mGrB showed 100-fold en-
hanced ability to kill P815 cells, with similar effi  ciency to hGrB 
(Fig. 5 D, left).
At present, the reason for the difference in mutant mGrB 
killing of the lymphoma cells (two- to fourfold increase) com-
pared with P815 cells (100-fold increase) is unclear, but it is 
possible that the altered mGrB cleaves a target in P815 cells 
that is absent from the lymphoma cells. Nevertheless, collec-
tively, the aforementioned results confi  rm that mGrB has a 
substrate binding cleft that is structurally distinct from hGrB, 
which  explains its different substrate specifi  city  profi  le  and 
killing mechanism.
Serpins that regulate hGrB and mGrB 
cytotoxicity are not conserved
hGrB is regulated by the intracellular protease inhibitor, PI-9, a 
member of the serpin superfamily (Bird et al., 1998; Hirst et al., 
2003). The serpin inhibitory mechanism requires recognition of 
an exposed reactive center loop (RCL) as a potential substrate 
by a cognate protease, followed by cleavage between the P1 and 
P1′ residues. This triggers conformational change in the serpin, 
distorting the active site of the protease and trapping an inter-
mediate consisting of the protease bound to the serpin (for 
  review see Gettins, 2002). hGrB cleaves the PI-9 RCL after 
Glu, consistent with its preference for acidic residues, and is 
very rapidly trapped (Sun et al., 2001).
Mice have seven PI-9 homologues (Kaiserman et al., 
2002), but the counterpart of PI-9 is not immediately obvious. 
The closest homologue, SPI6, has not been tested with mGrB 
but inhibits hGrB 20-fold slower than PI-9 (Sun et al., 1997). 
When overexpressed, SPI6 protects dendritic cells (Medema 
et al., 2001) and T cells (Phillips et al., 2004) from CL attack and 
increases the survival of CD8
+ memory cells (Phillips et al., 2004). 
Loss of SPI6 results in diminished survival of CTL (Zhang et al., 
2006). However, none of these studies has demonstrated that 
SPI6 directly or effi  ciently inhibits mGrB. To determine whether 
SPI6 is a mouse GrB inhibitor, we identifi  ed the cleavage site 
for mGrB in the SPI6 RCL and measured the kinetics of the 
  interaction, assessed the ability of SPI6 and mGrB to interact in 
CL extracts, and tested whether SPI6 protects cells against death 
mediated by purifi  ed mGrB and perforin.
The hGrB–PI-9 interaction requires cleavage of the PI-9 
RCL at Glu340 (Sun et al., 2001; Fig. 6 A), and mGrB also 
cleaves PI-9 at this point (unpublished data). N-terminal se-
quencing of the 6-kD fragment generated by treatment of SPI6 
with mGrB or hGrB showed that cleavage occurs at Cys339, 
adjacent to the predicted P1 Cys340 (Fig. 6 A). This is a previ-
ously unrecognized cleavage specifi  city of GrB and broadens 
the range of potential substrates.
Figure 4.  Structural differences in the S4 and S3 subsites of human and 
mouse GrB. (A) Interaction of the IEPD peptide with the active site cleft of 
hGrB. Shown is a section of the structure of hGrB (green ribbon) com-
plexed to the inhibitor IEPD-CHO (red stick; available from Protein Data 
Bank under accession no. 1IAU; Rotonda et al., 2001). Highlighted are 
the GrB residues Y174 and N218 predicted to interact with the P4 and P3 
residues of the peptide. The active site serine (S195) is also indicated. 
(B) Alignment of the human, mouse, and rat GrB sequences. This illustrates 
that Y174 and N218 are not conserved in the mouse. R226 (shown in 
  purple), which is at the bottom of the S1 pocket and interacts with P1 Asp, 
is conserved. Catalytic triad residues are indicated in yellow.JCB • VOLUME 175 • NUMBER 4 • 2006  624
Although cleavage at Cys339 might allow capture of some 
mGrB by SPI6, the kinetics of the interaction will indicate whether 
mGrB is effectively regulated by SPI6 in vivo. Accordingly, we 
measured the rate constant (kass) and stoichiometry of inhibition of 
SPI6 and mGrB complex formation (Table II). The results strongly 
suggest that SPI6 is a poor inhibitor of mGrB. The stoichiometry 
of inhibition indicates that fewer than one out of fi  ve contacts re-
sults in mGrB trapping, and the low kass indicates that complex for-
mation is very slow. SPI6 is even less effective in inhibiting hGrB 
(Table II). To put these results into context, PI-9 inhibits hGrB with 
equimolar stoichiometry and a rate of 1.2 × 10
6 M
−1s
−1 (Sun et al., 
2001). Furthermore, the inhibition of mGrB by SPI6 is slower than 
the inhibition of hGrB by the viral serpin CrmA (Quan et al., 1995), 
which does not block GrB-mediated apoptosis in vivo.
Another signature of a serpin–protease interaction is the for-
mation of SDS-stable complexes. For example, when human CLs 
are lysed, GrB is released from granules and rapidly binds cyto-
solic PI-9, and because GrB is in excess, essentially all of the PI-9 
moves into complex (Fig. 6 B, left; Hirst et al., 2003). Similarly, in 
extracts of mouse CLs probed with anti-mGrB or anti-SPI6 anti-
bodies, a complex containing mGrB and SPI6 was evident (Fig. 
6 B, right). However, less than half of the SPI6 moved into com-
plex, consistent with a less effi  cient interaction between this serpin 
and GrB, and indicating that the slow in vitro kinetics are not due 
to lack of a SPI6 cofactor present in CLs. To confi  rm that complex 
formation is GrB dependent, extracts were prepared from CLs 
taken from mice lacking GrB. No complex was evident in these 
cells (unpublished data).
If mouse and human GrB are orthologous, PI-9 and SPI6 
should provide cross-species protection from GrB-mediated cell 
death. To test this, we challenged mouse P815 cells expressing 
SPI6 with hGrB and human SKW6.4 cells expressing PI-9 with 
mGrB (Fig. 6 C). As expected, PI-9 protected SKW6.4 cells 
against hGrB (Fig. 6 C, top left), increasing the EC50  20-fold. 
SPI6 protected P815 cells against mGrB (Fig. 6 C, bottom right), 
increasing the EC50 >14-fold. Furthermore, the inactive 
SPI6T327R hinge mutant did not prevent mGrB-mediated death, 
indicating that the classic serpin inhibitory mechanism is involved 
in SPI6 cytoprotection (unpublished data). However, PI-9 did not 
protect cells against mGrB (Fig. 6 C, top right), nor did SPI6 ef-
fectively protect cells against hGrB (Fig. 6 C, bottom left).
Finally, the humanized mutant mGrB almost completely 
lost its ability to be regulated by SPI6, exhibiting a similar cyto-
toxicity profi  le to hGrB on SPI6-expressing cells (Fig. 5 D, 
right). This is consistent with the alterations to its active site 
cleft and substrate interactions and emphasizes the high speci-
fi  city of a cognate serpin–protease interaction. From the afore-
mentioned experiments, we concluded that mGrB is indirectly 
inhibited by SPI6 and that PI-9 and SPI6 are not functionally 
interchangeable. These results confi  rm that mGrB and hGrB 
have distinct substrate specifi  cities and indicate that they are 
regulated differently in vivo.
Mouse and human GrA have signiﬁ  cantly 
different cytotoxic potential
The functional differences that we identifi  ed between mGrB 
and hGrB raised the possibility that such interspecies differences 
Figure 5.  Humanized mGrB shows improved substrate cleavage and 
  cytotoxic potential. (A) Michaelis plots of peptide substrate cleavage by wt 
and humanized (mut) mGrB. Calculated speciﬁ   city constants for each 
  enzyme–substrate pair are tabulated below the plots. (B) Cleavage of mouse 
Bid and mouse procaspase 3 by wt and humanized mGrB. 
35S-labeled 
mouse procaspase 3 or Bid were incubated with wt mGrB or humanized 
mGrB at 37°C for 30 min. 100 μM z-VAD was included in parallel re-
actions to prevent the second step in caspase 3 activation. Products were sep-
arated by 15% SDS-PAGE and visualized by ﬂ  uorography. (C) Increased 
cytotoxicity of humanized mGrB on Bid+/+ and Bid−/− mouse lym-
phoma cells. Cells were incubated for 1 h with hGrB (closed squares; solid 
line), wt mGrB (closed triangles; solid line), or humanized mGrB (open 
  circles; dashed line) in the presence of perforin. Cell survival was assessed 
after 24 h by MTT assay. Collated EC50 values from these experiments and 
those described in Figs. 1 and 2 C are indicated below representative 
curves. (D) Increased cytotoxicity and lack of regulation of humanized 
mGrB by SPI6 in P815 cells. Symbols and lines are described in C.FUNCTIONAL DIVERGENCE OF HUMAN AND MOUSE GRANZYMES • KAISERMAN ET AL. 625
would also be evident in other granzymes. Although mouse and 
human GrA cleave the peptide substrate benzyloxy-carbonyl-
Lys-thiobenzyl ester with similar effi  ciency (Fig. 7 A; Odake 
et al., 1991), structural and substrate preference analysis of 
GrA has identifi  ed differences between the mouse and human 
enzymes in the active site cleft (Bell et al., 2003). This study 
identifi  ed an optimal P4-P1 substrate for hGrA as VANR¯, 
whereas the optimal mGrA substrate was identifi  ed as GYFR¯. 
Mutation of the hGrA S4 and S3 pockets converted it to a 
mouse-like GrA (Bell et al., 2003).
To determine whether these structural differences trans-
late into differences in cytotoxic potential, we compared the 
ability of mGrA and hGrA to kill human or mouse cells in 
the presence of perforin. We used two different death assays: 
our standard MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide) test, which measures loss of mitochondrial 
respiration (Fig. 7 C), and 
51Cr release, which measures loss of 
membrane integrity (Fig. 7 D). As shown in Fig. 7 (C and D), 
mGrA effi  ciently killed mouse and human cells, but hGrA did 
not. mGrA-induced death was perforin dependent, as cells ex-
posed to mGrA alone survived (Fig. 7 C). The inability of hGrA 
to kill cells was not related to the source of the protease, as both 
recombinant and native forms were used. All of the hGrA used 
was in the physiological 60-kD dimeric form, which could be 
reduced to the 30-kD monomeric form (Fig. 7 B). Monomeric 
hGrA also failed to kill cells (unpublished data).
Discussion
GrA and GrB are believed to be the primary cytotoxins in 
  human and mouse CLs. The evidence presented here clearly 
demonstrates substantial interspecies distinctions that suggest 
caution when using mouse models to elucidate the molecular 
and pathophysiological functions of these proteases in humans. 
For example, loss of GrB may be much more devastating to hu-
mans than the mild phenotype of GrB-defi  cient mice would 
suggest, given that hGrB is more effi  cient than mGrB and that 
hGrA is apparently nonlethal and could not compensate for 
GrB absence.
Such interspecies differences between granzymes are il-
lustrated by the GrB–Bid interaction, which indicates that dis-
tinct death pathways are initiated by hGrB and mGrB (Fig. 8 A). 
Our results show that hGrB is a much more effective killer than 
mGrB because it can cleave and activate Bid, whereas mGrB 
cleaves Bid poorly and does not require it for initiating  apoptosis. 
The requirement for Bid in hGrB-mediated killing is not an 
  artifact arising from its use on mouse target cells, as Bcl-2 over-
expression in human cells blocks hGrB cytotoxicity but can be 
relieved by Bid coexpression (Waterhouse et al., 2006). The 
failure of hGrB to kill in the absence of Bid indicates that it 
lacks the capacity to independently and fully activate effector 
caspases, as suggested previously (Goping et al., 2003; Sutton 
et al., 2003). Its ability to cleave other substrates must also be 
Figure 6.  hGrB and mGrB are regulated by distinct, species-speciﬁ  c serpins. 
(A) Comparison of PI-9 and SPI6 RCLs showing GrB cleavage sites identi-
ﬁ  ed by N-terminal sequencing. The predicted P1 residue is indicated in 
large, bold font. (B) Serpins, granzymes, and complexes in CL extracts 
were visualized by sequential immunoblotting. Lysis of cells in LSB traps 
preformed complex. Cell disruption in NP-40 and incubation for 10 min at 
37°C allows postlysis formation of complexes. (C) Species-speciﬁ  c protec-
tion by serpins from GrB-mediated death. Human SKW6.4 cells (closed 
squares; solid line) or SKW6.4 cells expressing PI-9 (open squares; dashed 
line) were incubated for 1 h with hGrB or mGrB in the presence of perforin. 
Cell survival was assessed after 24 h by MTT assay. Similar experiments 
were performed using mouse P815 cells (closed triangles; solid line) or 
P815 cells expressing SPI6 (open triangles; dashed line). Collated EC50 
values from these experiments and those described in Fig. 1 are indicated 
below representative curves.
Table II. Inhibition of GrB by SPI6
Parameter n mGrB hGrB
Stoichiometry of inhibition 3 5.8 ± 0.5 >10
Rate constant (kass M
−1s
−1) 2 5.6 ± 1.4 × 10
4 4.0 ± 0.3 × 10
3
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insuffi  cient to cause death. In contrast, mGrB probably directly 
activates another effector caspase, such as procaspase 7, or it 
  relieves IAP inhibition of caspase 3 independently of Bid. It 
may also cause caspase-independent death by cleaving sub-
strates such as ICAD or as-yet-undefi  ned mitochondrial targets 
(Thomas et al., 2001).
The differences between hGrB and mGrB are also empha-
sized by our ability to humanize mGrB and improve its capacity 
to cleave Bid. However, humanized mGrB remains relatively 
ineffi   cient compared with hGrB, indicating that additional 
changes to the mGrB substrate binding pocket are required to 
fully accommodate Bid. Supporting evidence for differences 
between mGrB and hGrB can also be found in previous studies. 
For example, synthetic catalytic inhibitors designed to hGrB do 
not inhibit mGrB (Willoughby et al., 2002); the human adeno-
viral protein L4-100K inhibits hGrB but not mGrB (Andrade et al., 
2003); mGrB does not process human Bid (Adrain et al., 2005); 
and mGrB does not require Bax or Bak for cytotoxicity, whereas 
hGrB does (Thomas et al., 2001; Cartron et al., 2003).
Similarly, hGrA and mGrA do not appear to be function-
ally equivalent, as we have shown that mGrA is cytotoxic and 
that hGrA is not. This is supported by several other lines of 
 evidence. Modeling of mGrA on the structure of hGrA has iden-
tifi  ed differences in their active site clefts, substantiated by 
differences in peptide substrate preference and the conversion 
of hGrA to an mGrA-like protease by mutation of the S4/S3 
pockets (Bell et al., 2003). Early work showed that mGrA is cyto-
toxic when produced with perforin in rat basophilic leukemia 
cells (Shiver et al., 1992), and many studies on the mechanisms 
of GrA-mediated death have used CTL and target cells from 
mice (Pardo et al., 2002, 2004). In contrast, recent studies using 
specifi  c inhibitors show that hGrA is a minor contributor to CL 
cytotoxicity (Mahrus and Craik, 2005). Such fi  ndings do not 
necessarily overturn the idea that hGrA engages apoptotic path-
ways by cleaving specifi  c subcellular proteins and generating 
reactive oxygen species (Pardo et al., 2004; Martinvalet et al., 
2005), but they suggest that it does so much less effi  ciently than 
mGrA and that it is not suffi  cient to induce cell death.
The differences between hGrB and mGrB also extend to 
their regulation, as indicated by differences between PI-9 and 
SPI6. PI-9 is an effi  cient hGrB inhibitor that protects CLs and 
Figure 7.  Mouse but not human GrA induces perforin-dependent cell death. 
(A) Progress curves of mGrA (closed boxes) and hGrA (open boxes)   cleaving 
benzyloxy-carbonyl-Lys-thiobenzyl ester, where 1 U of enzyme increases 
  absorbance by 1 milli-OD/min. mGrA contains 144 ± 5 U/μg, whereas 
hGrA contains 18 ± 2 U/μg. This is consistent with the difference in kcat/KM 
previously reported (Odake et al., 1991), conﬁ  rming that the enzymes are 
equally active. (B) 300 ng of recombinant hGrA was added to LSB with or 
without DTT and then boiled for 5 min before 10% gel SDS-PAGE and immuno-
blotting for hGrA. The image shows separated lanes originating from the 
same gel. (C) Human Jurkat cells or mouse lymphoma cells were incubated 
for 1 h with recombinant mGrA or recombinant hGrA in the presence or ab-
sence of perforin (Pf). Cell survival was assessed 24 h later by MTT assay. 
(D) HeLa cells were incubated for 4 h with recombinant hGrB, recombinant 
mGrA, or native hGrA in perforin. Cell survival was assessed by 
51Cr 
  release assay. Error bars indicate standard deviation (n = 8).
Figure 8.  Functional divergence of human and mouse GrB. (A) hGrB and 
mGrB differ in cytotoxicity because hGrB has the capacity to efﬁ  ciently ac-
tivate Bid and initiate the mitochondrial death pathway, whereas mGrB 
lacks this capacity and must proceed through less efﬁ  cient alternate path-
ways leading to activation of effector caspases or degradation of other 
death substrates. Activation of effector caspases 3 and 7 may also lead to 
a caspase ampliﬁ  cation loop via caspase 8–mediated Bid cleavage, al-
though the contribution of this loop to cell death is unclear. (B) Phylogram 
of selected mammalian species indicating expansion and divergence of 
GrB, GrH, and PI-9 homologues in rodents. GrB, GrH, and their homo-
logues are indicated above the relevant branch, and PI-9 and its homo-
logues are below. Dog, sheep, and rabbit have PI-9 genes with a conserved 
P1 Glu, and are thus considered orthologous to human. The question marks 
indicate genomes in which the GrB/H locus has not been sequenced or is 
too fragmented for analysis.FUNCTIONAL DIVERGENCE OF HUMAN AND MOUSE GRANZYMES • KAISERMAN ET AL. 627
  bystanders from misdirected GrB (Sun et al., 1996; Bird et al., 
1998; Hirst et al., 2003), and SPI6 is a putative counterpart of PI-9 
(Sun et al., 1997; Medema et al., 2001; Phillips et al., 2004). 
Mice lacking SPI6 have fewer CTL, and remaining CTL have 
fewer granules and less evidence of cytoplasmic mGrB (Zhang 
et al., 2006). Crossing SPI6-defi  cient mice with mGrB-defi  cient 
mice rescues the CTL defect, but because the latter mice also lack 
several mGrB paralogues (Pham et al., 1996), it cannot be as-
sumed that SPI6 directly controls mGrB. Although the accumu-
lating evidence is consistent with a cytoprotective role for both 
PI-9 and SPI6 in CLs, our present work strongly suggests that the 
question of the mechanism of cytoprotection by SPI6 remains 
open, as it is not an effective mGrB inhibitor. Given that other 
mGrB paralogues are cytotoxic, four possibilities exist: the 
primary target of SPI6 is a cytotoxic mGrB paralogue; SPI6 
simultaneously controls multiple mGrB paralogues through a 
one-size-fi  ts-all RCL; mGrB or paralogues activate a downstream 
apoptotic protease, which is effi  ciently inhibited by SPI6 (and not 
activatable by hGrB); or SPI6 protects granule integrity indepen-
dently of granzyme inhibition (in which case, PI-9 would be pre-
dicted to control GrB and independently protect granule integrity). 
We consider the last two possibilities more likely because they 
explain why the rat, which has a more human-like GrB (Harris 
et al., 1998), has an orthologue of SPI6 rather than PI-9.
Among mammals, the multiple granzyme and serpin genes 
found in rodents appear to be the exception rather than the rule 
(Fig. 8 B), and it is evident that GrB and PI-9 paralogues emerged 
after divergence of Lagomorpha and Rodentia. A priori, the dis-
appearance of the PI-9 RCL sequence from rodents suggests a 
fundamental change to the structure of mGrB, which we have 
confi  rmed by demonstrating that mGrB is catalytically distinct 
from hGrB and is not controlled by PI-9. Conversely, we have 
shown that hGrB is not controlled by SPI6. Although mGrB has 
changed, the GrB cleavage site in mouse Bid is conserved and is 
accessible to hGrB. Thus, it can be surmised that mGrB has lost 
cytotoxicity rather than hGrB gaining it. Conservation of the 
mouse Bid cleavage site suggests that another protease attacks it 
or that it serves another function in the molecule.
Why have these changes occurred in rodents? Given its 
role in immunity, the simplest explanation is that mGrB has 
evolved to target a virulence factor from a particular pathogen or 
to avoid inhibition by a specifi  c pathogen protein. Specifi  c tar-
geting of virulence factors has been demonstrated for another 
leukocyte protease, neutrophil elastase (Weinrauch et al., 2002). 
Duplication of mGrB to generate paralogues may have allowed 
compensating cytotoxic mechanisms to evolve and/or multiple 
virulence factors to be targeted. The former possibility is sup-
ported by the reported cytotoxic functions of GrC and GrF (Revell 
et al., 2005). The appearance of cytotoxic mGrB paralogues 
may have then driven the evolution of cognate PI-9 paralogues.
Although functioning primarily as a cytotoxin, GrB prob-
ably has other roles. For example, in humans it is found in testis 
and has been implicated in reproduction (Hirst et al., 2001). It 
may also be involved in extracellular matrix remodeling (Buzza 
et al., 2005). With multiple substrates and roles, it is easy to 
  envisage that particular functions of GrB may have devolved 
to separate mGrB paralogues in rodents. For example, mouse 
granyzme N appears to be restricted to the testis and may have 
assumed the testicular role of hGrB (Takano et al., 2004).
In closing, we have shown that mGrB is structurally and 
enzymatically distinct from hGrB and has a different killing 
mechanism. We have also shown that human GrA is not cyto-
toxic, whereas mGrA is substantially cytotoxic. Such species 
differences may also extend to granzymes M and K, but appro-
priate comparisons have yet to be made. It may be that the over-
all killing effi  ciency of human and mouse CLs is comparable 
and that the loss of GrB cytotoxicity in the mouse has been 
  offset by a gain in GrA cytotoxicity or the evolution of GrB 
  paralogues. Nevertheless, use of a granzyme from one species 
on cells or extracts from another species may produce misleading 
results because key substrates are missing or are ineffi  ciently 
cleaved because recognition sites are not conserved. Use of 
mice to test inhibitors of human granzymes will fail because 
differences in active site topology of the mouse enzymes will 
prevent inhibitor binding. Likewise, use of mice to study viral 
infection may be compromised, as conserved virus inhibitors 
(e.g., SPI2/CrmA, Bcl-2 homologues, and AdL4-100K homo-
logues) will interact differently with or fail to control mouse 
granzymes. Finally, use of mouse models to study the impact of 
granzymes on tumorigenesis is also problematic because the 
species-specifi  c death pathways and substrates outlined here 
imply that tumors will subvert the immune system differently in 
mice and humans by up- or down-regulating different proteins.
Materials and methods
Granzymes and serpins
Recombinant serpins were produced in Pichia pastoris as described previ-
ously (Sun et al., 1995, 1997). Recombinant granzymes were also pro-
duced from P. pastoris (Sun et al., 1999, 2004). To improve expression 
levels, the wt mGrB cDNA was modiﬁ   ed by QuikChange site-directed 
  mutagenesis (Stratagene) to remove a cryptic polyadenylation site, using the 
oligonucleotide 5′-C  A  C  T  G  T  G  A  A  G  G  A  A  G  T  A  T  A  A  T  C  A  A  T  G  T  C  A  C  T  T  T  G  G-
G  G  G  C  -3′ and its complement. The S4/S3 subsites in mGrB were mutated 
using the oligos 5′-G  A  G  T  C  C  T  A  C  T  T  T  A  A  A  A  A  T  T  A  T  T  A  C  A  A  C  A  A  A  A  C  C  A  A  T-
C  A  G  -3′ and its complement (R174Y) and 5′-T  C  C  T  A  T  G  G  A  T  A  T  A  A  T  G  A  T  G  G  T-
T  C  A  C  C  T  C  C  -3′ and its complement (K218N). Activity of recombinant GrB 
was   assessed by cleavage of the peptide substrate benzyloxycarbonyl-
AlaAlaAsp-thiobenzyl ester (Sun et al., 1999, 2004). The speciﬁ  c activity 
of hGrB was 90 U/μg, and the speciﬁ  c activity of mGrB was 120 U/μg. 
The proportion of active enzyme in each batch of puriﬁ  ed protein was 
estimated by the ability to complex with PI-9 or SPI-6. Routinely, >90% 
of granzyme in a batch could complex with the appropriate serpin. 
Native human GrA was from lymphokine-activated killer cells. Activity 
of GrA was assessed by cleavage of the substrate benzyloxycarbonyl-
Lys-thiobenzyl ester.
Kinetic analysis of substrate cleavage by granzymes 
and inhibition by serpins
Quenched ﬂ  uorescence substrates were synthesized and used as described 
previously (Sun et al., 2001). Activity of granzymes on the peptide sub-
strates Boc-AAD-thiobenzyl ester (BIOMOL Research Laboratories, Inc.) 
and IETD-pNA (Calbiochem) was assessed as described previously (Sun 
et al., 2001). Inhibition of granzymes by serpins was measured using 
standard approaches (Hopkins and Stone, 1995; Sun et al., 2001). 
Granzyme cleavage sites in SPI6 and PI-9 were identiﬁ  ed by N-terminal 
  sequencing (Sun et al., 2001).
Production of granzyme substrates via in vitro transcription 
and translation
35S-labeled mouse procaspase 3 or mouse Bid was produced from cDNAs 
in the expression vector pSVTf via in vitro transcription and translation (Sun 
et al., 2004). Cleavage by granzymes was assessed by adding a speciﬁ  ed JCB • VOLUME 175 • NUMBER 4 • 2006  628
amount of protease directly to the translation mix and incubating for 30 
min at 37°C. The caspase inhibitor z-VAD was obtained from Calbiochem. 
Products were separated by SDS-PAGE and visualized by ﬂ  uorography.
Analysis of granzyme substrate speciﬁ  city by phage display
Construction of substrate libraries based on bacteriophage T7 used the 
T7Select1-1b phage display system (Novagen). Each library was made by 
synthesizing a degenerate oligonucleotide, annealing it to complementary 
half-site oligonucleotides, ligating the resulting heteroduplex to vector 
arms, and adding it to a T7 phage packaging extract. The half-site oligo-
nucleotides were 5′-G  C  C  G  C  C  T  G  G  A  G  T  G  A  G  A  G  -3′ and 5′-A  G  C  T  T  A  G  T  G-
A  T  G  G  T  G  A  T  G  G  T  G  A  T  G  -3′. One library was constructed using the 
degenerate oligonucleotide 5′-A  A  T  T  C  T  C  T  C  A  C  T  C  C  A  G  G  C  G  G  C  (NNK)9C  A-
T  C  A  C  C  A  T  C  A  C  C  A  T  C  A  C  A  -3′ (where N represents any nucleotide and K 
represents T/C). This added a randomized nonameric peptide and a 
  hexahistidine tag to the C terminus of the 10B coat protein. The complexity 
of this “random” library was 7 × 10
6 plaque-forming units. Another 
library was constructed using 5′-A  A  T  T  C  T  C  T  C  A  C  T  C  C  A  G  G  C  G  G  C-
(NNK)3GAC(NNK)5C  A  T  C  A  C  C  A  T  C  A  C  C  A  T  C  A  C  A  -3′. This encoded an as-
partate near the middle of the randomized peptide. The complexity of this 
“ﬁ  xed” library was 4 × 10
6 plaque-forming units. Each library was ampli-
ﬁ  ed to >10
10 plaque-forming units. About 10
9 plaque-forming units of am-
pliﬁ   ed phage were bound to nickel-chelated Sepharose beads at 4°C. 
Unbound phage was removed by washing the beads in phosphate-  buffered 
saline containing 850 mM NaCl and 0.1% (vol/vol) Tween 20. After two 
further washes in phosphate-buffered saline containing 1 mM MgSO4, the 
suspension was split into two parts (treatment and control; control treat-
ments were performed to assess the extent of phage release from beads in 
the absence of protease). 200 nM granzyme was added to the treatment 
tube, and both tubes were incubated overnight at 37°C. Plaque-forming 
units in the supernatants representing cleaved or released phage were then 
counted and ampliﬁ  ed to form sublibraries for the next round of selection. 
Phage remaining bound to the beads was eluted with 0.5 M imidazole, 
and plaque-forming units were counted to assess cleavage efﬁ  ciency. After 
several selection rounds, individual plaques were chosen at random for se-
quence analysis. Phage DNA was ampliﬁ  ed by PCR using dedicated primers 
(T7Select cloning kit; Novagen). Sequencing of PCR products using the 
same primers was performed using the Big Dye 3.1 kit (GE Healthcare).
The sequencing results were analyzed to determine the statistical 
distribution of each amino acid at each position of the nonamer (Matthews 
et al., 1994), allowing for the redundancy of the code, the fact that only 
32 out of 64 codons are represented by NNK, and the exclusion from the 
analysis of any sequences encoding a stop codon in the nonamer. In a bi-
nomial distribution of amino acids, ∆σ yields the difference of the observed 
frequency from the expected frequency in terms of standard deviations:
 
() () () [] {} Ds = - -
1/ 2
() / 1 Obs x nP x nP x P x , 
where Obs(x) is the number of times amino acid x occurs in the selected 
  sequences, P(x) is the theoretical probability of amino acid x occurring, 
and n is the total number of sequences analyzed.
Cells, cell culture, and transfections
Human YT and Jurkat cells were maintained as described previously (Bird 
et al., 1998). Eμ-myc/bid−/− and Eμ-myc/bid+/+ mouse B cell lym-
phomas (Waterhouse et al., 2005) were obtained from R. Johnstone (Peter 
MacCallum Cancer Institute, Melbourne, Australia). Human SKW6.4 and 
mouse EL4 and YAC-1 cells were maintained in Dulbecco’s modiﬁ  ed Eagle 
medium containing 10% heat-inactivated fetal calf serum, 2 mM gluta-
mine, and 55 μM β-mercaptoethanol. P815 cells were maintained in RPMI 
1640 medium containing 10% heat-inactivated fetal calf serum, 2 mM 
  glutamine, and 55 μM β-mercaptoethanol. Isolation and culture of mouse 
splenocytes followed standard procedures.
To generate SKW6.4 cells stably expressing PI-9, a PI-9 expression 
vector (Bird et al., 1998) was cotransfected by electroporation with a plas-
mid expressing neomycin resistance, and selection was performed in 
1 mg/ml G418 (Sigma-Aldrich). Clones were established by limiting dilution 
and screened for PI-9 expression by indirect immunoﬂ  uorescence  and 
  immunoblotting. FLAG-tagged SPI6 and SPI6T327R (containing an inacti-
vating mutation in the proximal hinge) cDNAs were generated by PCR from 
the appropriate templates using the primer pair 5′-C  G  G  G  A  T  C  C  A  T  G  G  A-
C  T  A  C  A  A  A  G  A  C  G  A  T  G  A  C  G  A  T  A  A  A  G  G  G  A  A  T  A  C  T  C  T  G  T  C  T  G  A  A  G  -3′ and 
5′-G  C  T  C  T A  G  A T  T A T  G  G  A  G  A T  G  A  G  A  A  C  C  T  G  C  C  A  C  A  -3′. Products were cloned 
into the BamHI and XbaI sites of the expression vector pEF-PGKpuropA 
(Huang et al., 1997). 1.25 × 10
7 P815 cells were electroporated at 330 μF 
and 350 V with either pEFpuro/FlagSPI6 or pEFpuro/FlagSPI6T327R 
  vectors linearized with SalI. Transfected pools were grown for 3 d in 
1.1 μg/ml puromycin, and subsequently 45 SPI6 and 28 SPI6T327R lines 
were cloned by limiting dilution in puromycin selection. Clones were 
scored for relative SPI6 expression by indirect immunoﬂ  uorescence using 
the α-FLAG M2 antibody. Expression was conﬁ  rmed by immunoblotting using 
rabbit antiserum (R25) raised to recombinant SPI6. This antiserum does not re-
cognize the highly related mouse serpins (Serpinb9b, Serpinb9e, Serpinb6, 
Serpinb6b, and Serpinb1) and can be considered speciﬁ  c for SPI6.
Cytotoxicity assays
Cell death mediated by granzymes and recombinant perforin was as-
sessed as previously described (Sun et al., 2004; Bird et al., 2005). 
  Recombinant perforin was produced using a baculovirus expression   system 
(Liu et al., 1994). Recombinant SLO was prepared and used according to 
Walev et al. (2001).
Preparation of cell extracts, antibodies, and immunoblotting
For analysis of serpin complexes, cells were lysed in either 1 volume of 
Laemmli sample buffer (LSB) or 1/2 volume of NP-40 lysis buffer (50 mM 
Tris HCl, pH 8.0, 10 mM EDTA, and 1% [vol/vol] Nonidet P40), followed 
by incubation at 37°C for 10 min, after which 1/2 volume of 2× LSB was 
added. Viscosity was reduced by mechanically shearing the DNA using a 
needle and syringe. For analysis of caspase 3 cleavage, cells were lysed 
in NP-40 lysis buffer containing 1 μg/ml pepstatin, 1 μg/ml leupeptin, 
1 μg/ml aprotinin, and 10 μg/ml PMSF, and a postnuclear supernatant 
was prepared by centrifugation at 16,000 g. Antibodies to PI-9 (R15) 
and hGrB (2C5 hybridoma supernatant) were used for immunoblotting at 
1:2,000 and 1:100, respectively. A rat monoclonal antibody against mGrB 
was obtained from eBioscience (clone 16G6) and was used at 1:1,000. 
Goat anti-actin sera (Santa Cruz Biotechnology, Inc.) was used at 1:1,000. 
Rabbit antisera to SPI6 (R25) and hGrA (R045) was raised against recom-
binant protein puriﬁ  ed  from  P. pastoris following standard procedures 
and was used at 1:1,000. Rabbit antisera to caspase 3 (Cell Signaling 
Technology) was used at 1:100. HRP-conjugated secondary   antibodies 
was used at 1:5,000 and detected using enhanced chemiluminescence.
Image acquisition and manipulation
Images of blots were initially captured on x-ray ﬁ   lms, which were sub-
sequently scanned into Photopaint (Corel). Adjustments to brightness or 
contrast of digital images were applied to the whole image. No nonlinear 
adjustments were made.
Online supplemental material
Fig. S1 shows a comparison of methods used to assess cell survival 
  after GrB treatment. Fig. S2 shows a comparison of uptake of mGrB 
and hGrB into target cells. Fig. S3 shows GrB-mediated procaspase 3 
cleavage in Bid+/+ or Bid−/− mouse B cell lymphoma extracts. Online 
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200606073/DC1.
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